Table 1.
Characteristics | Baseline |
---|---|
Demographic | |
Patient numbers | 96 |
Age, Median [IQR] | 62 [10.25] |
Gender, male [%] | 41 [42.71%] |
Education, high school or higher [%] | 57 [59.38%] |
Clinical | |
Disease duration, Median [IQR] | 9 [6] |
HY stage (the “OFF” status) | |
I/II/III/IV/V | 0/53/35/6/2 |
MDS-UPDRS-III (the “OFF” status), Median [IQR] | 57 [26] |
MDS-UPDRS-III (the “ON” status), Median [IQR] | 30.5 [20] |
MDS-UPDRS-III improvement rate, Median [IQR] | 47.3% [26.19%] |
LEDD (mg), Median [IQR] | 300 [75] |
LEDD, levodopa-equivalent daily dose; SD, standard deviation; IQR, interquartile range; HY stage, Hoehn & Yahr stage.